{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:15:52Z","timestamp":1788311752644,"version":"build-2803163510"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.juro.2017.08.106","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T06:35:14Z","timestamp":1504334114000},"page":"407-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer"],"prefix":"10.1097","volume":"199","author":[{"given":"Alejandro","family":"Sanchez","sequence":"first","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Wszolek","sequence":"additional","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Niemierko","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Clayman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Drumm","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayron","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Dahl","sequence":"additional","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall M.","family":"Heney","sequence":"additional","affiliation":[{"name":"Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William U.","family":"Shipley","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"Zietman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.08.106_bib1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","article-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines","volume":"65","author":"Witjes","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.106_bib2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.106_bib3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.106_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.08.106_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1464-410X.2012.11476.x","article-title":"Management of local recurrences in the irradiated bladder: a systematic review","volume":"110","author":"Sapre","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2017.08.106_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.juro.2011.09.159","article-title":"Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer","volume":"187","author":"Eswara","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.08.106_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0090-4295(01)01219-5","article-title":"Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder","volume":"58","author":"Zietman","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.juro.2017.08.106_bib8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.ijrobp.2007.08.007","article-title":"Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy","volume":"70","author":"Weiss","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2017.08.106_bib9","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99\u201306","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.08.106_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11934-012-0301-x","article-title":"Trimodality therapy for bladder conservation in treatment of invasive bladder cancer","volume":"14","author":"Mitin","year":"2013","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.juro.2017.08.106_bib11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.08.106_bib12","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.08.106_bib13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.1991.9.9.1533","article-title":"Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy","volume":"9","author":"Fung","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.08.106_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/jjco\/hys105","article-title":"Analysis of Intravesical recurrence after bladder-preserving therapy for muscle-invasive bladder cancer","volume":"42","author":"Onozawa","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.juro.2017.08.106_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.106_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717774265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717774265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.08.106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:04:44Z","timestamp":1651208684000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.08.106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1016\/j.juro.2017.08.106"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.08.106","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.08.106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}